In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of Gram-negative bacilli and Staphylococcus aureus

Diagnostic Microbiology and Infectious Disease

Volumn 35, Issue 2, 1999, Pages 121-126

  Tallis, Eran ^a   Rudensky, Bernard ^a   Attias, Denise ^a   Raveh, David ^a   Schlesinger, Yechiel ^a   Yinnon, Amos M ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

CEPHALOSPORINS; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 0032741788     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00062-0     Document Type: Article

References (24)

1. Barradell L.B., Bryson H.M. Cefepime A review of its antibacterial activity, pharmacokinetic properties and therapeutic use . Drugs. 47:1994;471-505.
2. Cormican M.G., Marshall S.A., Jones R.N. Detection of extended-spectrum β-lactamase (ESBL)-producing strains by the E test ESBL screen. J Clin Microbiol. 34:1996;1880-1884.
3. Couldron P.E., Moland E.S., Sanders C.C. Occurrence and detection of extended-spectrum β-lactamases in members of the family Enterobacteriaeae at a veterans medical center Seek and you may find . J Clin Microbiol. 35:1997;2593-2597.
4. Emery C.L., Weymouth L.A. Detection and clinical significance of extended-spectrum β-lactamases in a tertiary-care medical center. J Clin Microbiol. 35:1997;2061-2067.
5. Fung-Tomc J., Dougherty T., DeOrio F., Simich-Jacobson V., Kessler R.E. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to β-lactamase levels. Antimicrob Ag Chemother. 33:1989;489-502.
6. Jacoby G.A., Han P. Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol. 34:1996;908-911.
7. Jones R.N. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med. 100:(suppl 6A):1996;3S-12S.
8. Jones R.N., Pfaller M.A., Doern G.V., Erwin M.E., Hollis R.J., et al. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs A 1997 surveillance trial in 102 medical centers in the United States . Diagn Microbiol Infect Dis. 30:1998;215-228.
9. Jones R.N., Salazar J.C., Pfaller M.A., Doern G.V. Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia using the E-test method. The Colombian antimicrobial resistance study group. Diagn Microbol Infect Dis. 29:1997;265-272.
10. Kessler R.E., Fung-Tomc J. Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year period. Am J Med. 100:(6A):1996;13S-19S.
11. Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard M2-A6 . 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.
12. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Approved Standard M7-A4 . 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.
13. Performance standards for antimicrobial susceptibility testing Ninth informational supplement . NCCLS. 19:(1):1999;M100-M1S9.
14. Neu H.C. Safety of cefepime A new extended-spectrum parenteral cephalosporin . Am J Med. 100:(suppl 6A):1996;68S-75S.
15. Pechere J.C., Vladoianu I.R. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob Chemother. 29:1992;563-573.
16. Pena C., Pujol M., Ricart A., Ardanuy C., Ayats J., Linares J., Garrigosa F., Ariza J., Gudiol F. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unit. J Hospital Infect. 35:1997;9-16.
17. Pfaller M.A., Marshall S.A., Jones R.N. In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci a multicenter sample . Diagn Microbiol Infect Dis. 29:1997;273-276.
18. Pfaller M.A., Jones R.N., Marshall S.A., Coffman S.L., Hollis J.R., Edmond M.B., Wenzel R.P. Inducible Amp C β-lactamase producing gram-negative bacilli from blood stream infections Frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE) . Diagn Microbiol Infect Dis. 28:1997;211-219.
19. Sanders W.E., Tenney J.H., Kessler R.E. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis. 23:1996;454-461.
20. Thornsberry C., Yee Y.C. Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods. Am J Med. 100:(6A):1996;26S-38S.
21. Vercauteren E., Descheemaeker P., Ieven M., Sanders C.C., Goosens H. Comparisons of screening methods for detection of extended spectrum β-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital. J Clin Microbiol. 35:1997;2191-2197.
22. Wynd M.A. Cefepime A fourth generation parenteral cephalosporin . Ann Pharmacother. 30:1996;1414-1424.
23. Yinnon A.M., Butnaru A., Raveh D., Jerassy Z., Rudensky B. A six year survey of Klebsiella bacteremia Community versus nosocomial infection . Quart J Med. 89:1996;933-941.
24. Yinnon A.M., Schlesinger Y., Gabbay D., Rudensky B. Analysis of five years of bacteremias Importance of stratification of microbial susceptibilities by source of patients . J Infect. 35:1997;17-23.